Novo Nordisk A/S
XMUN:NOV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
N
|
Novo Nordisk A/S
XMUN:NOV
|
DK |
|
P
|
Praram 9 Hospital PCL
SET:PR9
|
TH |
|
3
|
3S Korea Co Ltd
KOSDAQ:060310
|
KR |
|
MaxCyte Inc
LSE:MXCT
|
US |
|
Karsu Tekstil Sanayi ve Ticaret AS
IST:KRTEK.E
|
TR |
|
Applus Services SA
MAD:APPS
|
ES |
|
R
|
Rex Trueform Group Ltd
JSE:RTN
|
ZA |
Wall Street
Price Targets
NOV Price Targets Summary
Novo Nordisk A/S
According to Wall Street analysts, the average 1-year price target for
NOV
is 43.17 EUR
with a low forecast of 23.81 EUR and a high forecast of 62.81 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is NOV's stock price target?
Price Target
43.17
EUR
According to Wall Street analysts, the average 1-year price target for
NOV
is 43.17 EUR
with a low forecast of 23.81 EUR and a high forecast of 62.81 EUR.
What is Novo Nordisk A/S's Revenue forecast?
Projected CAGR
1%
For the last 14 years the
compound annual growth rate for
Novo Nordisk A/S's revenue is
12%.
The projected
CAGR
for the next 3 years is
1%.
What is Novo Nordisk A/S's Operating Income forecast?
Projected CAGR
2%
For the last 14 years the
compound annual growth rate for
Novo Nordisk A/S's operating income is
13%.
The projected
CAGR
for the next 3 years is
2%.
What is Novo Nordisk A/S's Net Income forecast?
Projected CAGR
0%
For the last 14 years the
compound annual growth rate for
Novo Nordisk A/S's net income is
14%.
The projected
CAGR
for the next 3 years is
0%.
